India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

India's Biocon posts higher quarterly profit on boost from generics, biosimilar business Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its ...